Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Tacrolimus and Methotrexate for GVHD Prevention
NCT01789255Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2013
- Primary completion
- Mar 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in graft-versus-host disease (GVHD), sponsored by National Cancer Institute. Started Jun 2013; status: completed.
02
Drugs
vorinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01789255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789255.